AlloVir, Inc. (NASDAQ:ALVR) Shares Sold by Marshall Wace LLP

Marshall Wace LLP lessened its stake in AlloVir, Inc. (NASDAQ:ALVR) by 11.1% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 324,658 shares of the company’s stock after selling 40,478 shares during the period. Marshall Wace LLP owned 0.28% of AlloVir worth $234,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Twin Focus Capital Partners LLC acquired a new position in AlloVir in the 4th quarter valued at about $40,000. Price T Rowe Associates Inc. MD increased its position in AlloVir by 127.4% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 97,986 shares of the company’s stock worth $74,000 after purchasing an additional 54,900 shares during the period. Marquette Asset Management LLC acquired a new position in AlloVir during the 1st quarter worth approximately $135,000. Finally, Acadian Asset Management LLC increased its position in AlloVir by 694.6% during the 1st quarter. Acadian Asset Management LLC now owns 1,587,451 shares of the company’s stock worth $1,197,000 after purchasing an additional 1,387,666 shares during the period. Institutional investors and hedge funds own 66.05% of the company’s stock.

AlloVir Trading Up 3.4 %

NASDAQ ALVR opened at $0.84 on Friday. The business’s 50 day moving average is $0.77 and its two-hundred day moving average is $0.77. AlloVir, Inc. has a 12-month low of $0.58 and a 12-month high of $2.49. The stock has a market capitalization of $96.90 million, a price-to-earnings ratio of -0.68 and a beta of 0.79.

AlloVir (NASDAQ:ALVR) last released its earnings results on Wednesday, August 14th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.05. Equities analysts forecast that AlloVir, Inc. will post -0.5 earnings per share for the current fiscal year.

About AlloVir

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus.